Dryocrassin ABBA
Dryocrassin ABBA can significantly suppress tumor growth, without major side effects, it may induce apoptosis in human hepatocellular carcinoma cells through a caspase-mediated mitochondrial pathway. Orally administered dryocrassin ABBA provides mice protection against avian influenza virus H5N1 by inhibiting inflammation and reducing virus loads; dryocrassin ABBA is a potential novel lead compound which has antiviral effects on amantadine-resistant avian influenza virus H5N1 infection.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Int J Mol Sci.2021, 22(21):11447.
Sci Rep.2023, 13(1):7475.
J Pain Res.2022, 15:3469-3478.
Molecules2022, 27(11):3606.
Hum Exp Toxicol.2017, 36(11):1169-1176
BMC Microbiol.2019, 19(1):78
Plants (Basel).2021, 10(5):951.
J of the Korean Society of Cosmetics and Cosmetology2018, 399-406
Korean J. Medicinal Crop Sci.2018, 26(2):148-156
Pharmacognosy Magazine2017, 13(52):868-874
Related and Featured Products
Asian Pac J Cancer Prev. 2016;17(4):1823-8.
Dryocrassin ABBA Induces Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells Through a Caspase-Dependent Mitochondrial Pathway.[Pubmed:
27221859]
Biological and pharmacological activities of Dryocrassin ABBA, a phloroglucinol derivative extracted from Dryopteris crassirhizoma, have attracted attention. In this study, the apoptotic effect of Dryocrassin ABBA on human hepatocellular carcinoma HepG2 cells was investigated.
METHODS AND RESULTS:
We tested the effects of Dryocrassin ABBA on HepG2 in vitro by MTT, flow cytometry, real-time PCR, and Western blotting. KM male mice were used to detect the effect of Dryocrassin ABBA on H22 cells in vivo.
Dryocrassin ABBA inhibited the growth of HepG2 cells in a concentration-dependent manner. After treatment with 25, 50, and 75 μg/mL Dryocrassin ABBA, the cell viability was 68%, 60% and 49%, respectively. Dryocrassin ABBA was able to induce apoptosis, measured by propidium iodide (PI)/annexin V-FITC double staining. The results of real-time PCR and Western ting showed that Dryocrassin ABBA up-regulated p53 and Bax expression and inhibited Bcl-2 expression which led to an activation of caspase-3 and caspase-7 in the cytosol, and then induction of cell apoptosis. In vivo experiments also showed that Dryocrassin ABBA treatment significantly suppressed tumor growth, without major side effects.
CONCLUSIONS:
Overall, these findings provide evidence that Dryocrassin ABBA may induce apoptosis in human hepatocellular carcinoma cells through a caspase-mediated mitochondrial pathway.
Front Microbiol., 2015, 6:592.
Dryocrassin ABBA, a novel active substance for use against amantadine-resistance H5N1 avian Influenza virus[Reference:
WebLink]
The occurrence of multi-drug resistant highly pathogenic avian influenza virus (HPAIV) strains highlights the urgent need for strategies for the prevention and control of avian influenza virus. The aim of our current study is to evaluate the antiviral activity of Dryocrassin ABBA isolated from Rhizoma Dryopteridis Crassirhizomatis (RDC) against an amantadine-resistant H5N1 (A/Chicken/Hebei/706/2005) strain in a mouse model.
METHODS AND RESULTS:
Post inoculation with HPAIV H5N1 virus in mice, the survival rate was 87, 80, and 60% respectively in the 33, 18, and 12.5 mg/kg Dryocrassin ABBA-treated groups. On the other hand, the survival rate was 53 and 20%, respectively in the amantadine-treated group and untreated group. Mice administered with Dryocrassin ABBA or amantadine showed a significant weight increase compared to the untreated group. Moreover, 33 and 18 mg/kg Dryocrassin ABBA have decreased lung index (P >0.05) and virus loads (P <0.01) compared to the untreated group on day 7. Also, on day 7 bronchoalveolar lavage fluid pro-inflammatory cytokines (IL-6, TNF-α, and IFN-γ) decreased significantly (P <0.01) while anti-inflammatory cytokines (IL-10 and MCP-1) were increased significantly (P <0.01) in the 33 and 18 mg/kg Dryocrassin ABBA-treated groups compared to the amantadine group and the untreated group. Moreover, the concentrations of IL-12 in drug-treated groups were significantly (P < 0.01) lowered compared with the untreated group.
CONCLUSIONS:
Based on the above we conclude that orally administered Dryocrassin ABBA provided mice protection against avian influenza virus H5N1 by inhibiting inflammation and reducing virus loads.
Dryocrassin ABBA is a potential novel lead compound which had antiviral effects on amantadine-resistant avian influenza virus H5N1 infection.
Biomed Chromatogr. 2014 Sep;28(9):1205-11.
Application of a sensitive and accurate LC-MS/MS method for determination of dryocrassin ABBA in rat plasma for a bioavailability study.[Pubmed:
24497015]
METHODS AND RESULTS:
A sensitive and accurate liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of Dryocrassin ABBA, a potential active component isolated from Dryopteris crassirhizoma, in rat plasma. Chromatographic separation was achieved on a Zorbax SB-C18 column (50 × 2.1 mm, 1.8 µm), with elution consisting of eluent (A) 10 mm ammonium acetate in methanol containing 0.1% formic acid and (B) 10 mm ammonium acetate in water containing 0.1% formic acid (A:B = 99:1, v/v) at a flow rate of 0.3 mL/min. Multiple reaction monitoring mode was used to monitor the precursor-product ion transitions of m/z 819.3 → 403.4 for Dryocrassin ABBA and m/z 426.2 → 409.2 for internal standard. This assay exhibited a good linearity with a correlation coefficient >0.99 and showed no endogenous interference with the analyte and internal standard. The lower limit of quantification of Dryocrassin ABBA was 4 ng/mL in 50 μL of rat plasma.
CONCLUSIONS:
The method was successfully applied in the pharmacokinetic study of Dryocrassin ABBA in rats after intravenous (2.35 mg/kg) and oral (23.5 mg/kg) doses of Dryocrassin ABBA. The oral bioavailability (F) of Dryocrassin ABBA was estimated to be 50.1%. Our study is the first to clarify the pharmacokinetic behaviors of Dryocrassin ABBA in animals.
